Skip to content
Business Company News, Medical Health Aged Care

Fresenius Medical Care ANZ manufacturing plant accelerates sustainability goals with renewable energy

Fresenius Medical Care ANZ 3 mins read

Local manufacturing operations now even more environmentally sustainable as cutting-edge solar panels installed

Sydney, Australia, 8 August 2023: Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, proudly announced the introduction of renewable solar energy at their plant in Smithfield, with an event on Friday 7th July.

The event, attended by Dr. Hugh McDermott, State Member for New South Wales, marked Fresenius Medical Care’s commitment to environmental stewardship and their role as pioneers in sustainable healthcare manufacturing.

The facility in Sydney’s Western Suburbs integrates cutting-edge sustainable practices into its production operations to minimize environmental impact and prioritizes the long-term wellbeing of patients and the local community. The installation of 537 Risen 540W solar panels, supported by 3x 50kW and 1x 110kW Sungrow inverters, now takes the organization closer to reaching its global emissions targets. The 290kW solar system is expected to avoid 342 tonnes of CO2 emissions per year, equivalent to the carbon sequestered by planting 64,871 trees. Moreover, the system will provide 84% of the plant's energy needs, resulting in a 52% reduction in grid consumption and avoiding 7,222 long-haul flights worth of emissions annually.

"As a leading global provider of renal health products and services, Fresenius Medical Care has a special responsibility to its patients, which includes a firm focus on environmental sustainability," states John Amiradaki, General Manager, Manufacturing & Supply Chain at Fresenius Australia. "At Fresenius Medical Care, we understand that manufacturing excellence goes hand in hand with environmental responsibility. That's why we have embraced the power of renewable energy to drive our operations forward."

"At Fresenius Medical Care ANZ, we are committed to making a positive impact on the environment while delivering life-changing medical care," says Greg Kozma, General Manager Australia and New Zealand, Care Enablement. "By utilizing solar power, we reduce our carbon footprint and help take our organisation towards its global climate goals."

Fresenius Medical Care continuously explores innovative technologies and eco-friendly practices to minimize waste, conserve resources, and reduce its ecological impact. The organization’s commitment to sustainability future-proofs its manufacturing operations for generations to come.

## ENDS ##


About us:

ABOUT FRESENIUS MEDICAL CARE

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,153 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). 

For more information, please visit the company’s website: www.freseniusmedicalcare.asia

DISCLAIMER

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. 

 


Contact details:

Helen Skazas - Marketing Manager ANZ

Ph: 02 9466 8000

Fresenius Medical Care ANZ
Lv3, 78 Waterloo Rd 

Macquarie Park, NSW 2113, Australia

 

 

Media

More from this category

  • Business Company News, Oil Mining Resources
  • 17/12/2025
  • 13:15
RocketDNA (ASX:RKT)

RocketDNA Receives ~A$1M in New Orders

HIGHLIGHTS New 12-month order fromBHP WAIO for dual xBot deployment Contract renewal and expansion atAssmang’s Khumani Iron Ore Mine, including a 12-month drone services extension and an additional 12-month xBot program Additional xBot units ordered by Norton Gold Fields Aggregate value of new binding contracts and purchase orders received of approximately A$1.0 million 17 December 2025, RocketDNA Ltd (ASX: RKT) (RocketDNA or the Company), a technology services company specialising in AI-powered drone data solutions, has received approximately A$1M in new purchase orders from existing customers, relating to the expansion of existing autonomous drone programs. These orders reflect increasing demand for…

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.